Pharmaceuticals, Biotechnology and Life Sciences
DCVAC/OvCa decreased the risk of death in second line treatment of ovarian cancer by 62% Overall survival (OS) increased significantly by…
DUBLIN–(BUSINESS WIRE)–The “Bone Cancer Treatment Market – Growth, Trends, and Forecast (2019 – 2024)” report has been added to ResearchAndMarkets.com’s…
GREENVILLE, SC.–(BUSINESS WIRE)–KIYATEC, Inc. today announced that the company has opened Inova Health System (Inova) and Roswell Park Comprehensive Care…
Eli Lilly’s Phase 3 RELAY study of Cyramza showed improvement in the time patients lived without their cancer growing or spreading after starting treatment, the company said Tuesday.
Pfizer got approval for Trazimera n USA for the treatment of human epidermal growth factor receptor-2 (HER2) overexpressing breast cancer and HER2 adenocarcinoma.
Roche said Monday it got accelerated approval to Tecentriq plus chemotherapy for the treatment of adults with unresectable triple-negative breast cancer (TNBC) in people whose tumours express PD-L1, as determined by an FDA-approved test.
Bexion’s Phase I First-In-Human Trial using BXQ-350 for the treatment of cancer has exceeded expectations in screening and enrollment at their 4 trial sites.
Taiho Oncology got aproval to have its Lonsurf as a treatment for adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma in the United States.
Torque will test its Deep IL-15 Primed T Cells (TRQ-1501) with Merck, both as a single agent and in combination with Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in a Phase 1/2 study in multiple solid tumor indications.
Xencor has put on hold one of its studies on myeloid leukemia CD123 x CD3 bispecific antibody molecule XmAb14045, until the FDA lifts the hold, the company said Wednesday in a press release.